Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Cytotherapy. 2014 Feb;16(2):149–159. doi: 10.1016/j.jcyt.2013.11.010

Table 4.

T cell therapy for adenovirus infection after stem cell transplant

Reference n HSCT type Strategy End points Results
Feuchtinger, 2006(38) 9 MRD, MUD, MMUD, haplo Treatment (refractory/unresponsive to antiviral drugs) Safety Efficacy CTL expansion

  • 1 case of aggravated pre-existing GvHD

  • AdV-specific T cells detectable in 5/6 patients

  • 5/6 patients cleared AdV
Leen, 2006(11) and Hanley 2013(15) 34 MRD, MUD, haplo Prophylaxis Safety Efficacy CTL expansion

  • No GvHD

  • 11/12 patients with AdV cleared the virus

  • Rise in AdV-specific T cells in patients with AdV infection
Leen, 2009(46) 13 MUD, haplo Prophylaxis (12)
Treatment (1)		 Safety Efficacy CTL expansion

  • No GvHD

  • 10 patients remained AdV free

  • 2 patients developed AdV and cleared after CTL infusion

  • Rise in AdV-specific T cells only in patients with AdV infection
Hanley, 2012(51) 7 cord blood Prophylaxis Treatment Safety Efficacy CTL expansion

  • No de novo GvHD

  • 6 patients remained AdV-free

  • ➢ 1 patient developed AdV infection and cleared spontaneously

  • Detectable AdV-specific T cells in patient with AdV infection

MRD: matched related donor, MUD: matched unrelated donor, haplo: haploidentical HSCT, CTL: cytotoxic T lymphocytes, GvHD: graft-versus-host disease, AdV: adenovirus.